Eli Lilly 称 retatrutide 在糖尿病研究中优于 Novo Nordisk 的 Ozempic
STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Eli Lilly 周三表示，其研究性药物 retatrutide 在一项大型糖尿病研究中，降糖与减重效果均优于 Novo Nordisk 的 Ozempic。最高剂量组治疗 80 周后 A1c 下降 2.2 个百分点，Ozempic 组下降 1.8 个百分点；体重分别下降 20.9% 和 9.4%。上述结果基于仅分析坚持治疗者的数据，而非全部受试者。
同一件事，精选收录的是《礼来 retatrutide 头对头 III 期 TRANSCEND-T2D-2 结果优于 Ozempic 2 mg》
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Eli Lilly on Wednesday said that its investigational drug was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study, further boosting the competitive profile of its medicine.
In the head-to-head study, people on the highest dose of Lilly’s drug, called retatrutide, saw a 2.2 percentage-point reduction in a measure of blood sugar called A1c after 80 weeks, while those on Ozempic saw a 1.8 percentage-point reduction.
Those on the highest dose of retatrutide also lost 20.9% of their weight, a highly significant amount considering that people with diabetes don’t tend to lose much weight on drugs. Meanwhile, those taking Ozempic lost 9.4% of their weight. These results are based on analyses looking only at the participants who stayed on treatment, not all participants.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源：STAT News · statnews.com